The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study.
Front Pharmacol
; 11: 1007, 2020.
Article
en En
| MEDLINE
| ID: mdl-32719607
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Front Pharmacol
Año:
2020
Tipo del documento:
Article
País de afiliación:
Bélgica